Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
RAPP 
Rapport Therapeutics, Inc. Common Stock (RAPP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/05/2025: RAPP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $51.5
1 Year Target Price $51.5
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -7.97% | Avg. Invested days 25 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.41B USD | Price to earnings Ratio - | 1Y Target Price 51.5 |
Price to earnings Ratio - | 1Y Target Price 51.5 | ||
Volume (30-day avg) 5 | Beta - | 52 Weeks Range 6.43 - 42.27 | Updated Date 12/7/2025 |
52 Weeks Range 6.43 - 42.27 | Updated Date 12/7/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.27 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -15.89% | Return on Equity (TTM) -23.41% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 904849571 | Price to Sales(TTM) - |
Enterprise Value 904849571 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 47661138 | Shares Floating 30413049 |
Shares Outstanding 47661138 | Shares Floating 30413049 | ||
Percent Insiders 4.68 | Percent Institutions 103.88 |
Upturn AI SWOT
Rapport Therapeutics, Inc. Common Stock
Company Overview
History and Background
Rapport Therapeutics is a clinical-stage biotechnology company focusing on developing precision medicines for neurological disorders. Founded in 2022, it aims to address significant unmet needs in epilepsy, pain, and other neurological conditions through targeted therapies.
Core Business Areas
- Drug Development: Discovery and development of novel therapeutics for neurological disorders, focusing on selective targeting of specific brain circuits and cell types.
- Precision Medicine: Employing advanced technologies to identify patient subpopulations most likely to benefit from their therapies.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their drug candidates.
Leadership and Structure
Rapport Therapeutics is led by a management team with experience in drug development and neuroscience. The organizational structure is typical for a biotech company, with research, development, clinical, and administrative functions.
Top Products and Market Share
Key Offerings
- RAP-219 (Epilepsy): RAP-219 is Rapport's lead drug candidate, a selective neuronal modulator being developed for drug-resistant focal epilepsy. Currently in Phase 1 clinical trials. Market share data is not yet applicable as the drug is not approved. Competitors include existing anti-epileptic drugs from companies like UCB (UCBJF) and Eisai (ESALY), as well as other companies developing novel therapies like SK Biopharmaceuticals (326030.KS).
- RAP-198 (Neuropathic Pain): RAP-198 is being developed for neuropathic pain. Currently in preclinical stages. Market share data is not yet applicable as the drug is not approved. Competitors include pharmaceutical companies selling pain medications such as Pfizer (PFE), Eli Lilly (LLY), and Johnson & Johnson (JNJ), as well as companies developing novel pain therapies like Vertex Pharmaceuticals (VRTX).
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on neurological disorders is characterized by high unmet medical needs, significant market potential, and intense competition. Advances in neuroscience and drug development technologies are driving innovation.
Positioning
Rapport Therapeutics is positioned as an innovator in precision neuroscience, focusing on developing targeted therapies for specific patient populations. Their competitive advantage lies in their ability to selectively modulate neuronal activity to address the underlying causes of neurological disorders.
Total Addressable Market (TAM)
The global market for epilepsy and neuropathic pain treatments are estimated at billions of dollars annually. Rapport Therapeutics aims to capture a significant share of this market by developing more effective and targeted therapies. The epilepsy market is projected to reach $12.1 billion by 2029. Rapport is positioned to access this TAM pending successful trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Strong scientific expertise in neuroscience
- Proprietary technology platform for precision drug development
- Experienced management team
- Promising lead drug candidate (RAP-219)
Weaknesses
- Early-stage company with limited revenue
- High reliance on clinical trial success
- Limited financial resources compared to larger pharmaceutical companies
- Drug development is very uncertain
Opportunities
- Large unmet medical need in neurological disorders
- Potential for partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas within neuroscience
- Positive clinical trial results could lead to significant market value increase
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- UCBJF
- ESALY
- PFE
- LLY
- JNJ
- VRTX
- SK Biopharmaceuticals(326030.KS)
Competitive Landscape
Rapport Therapeutics competes with established pharmaceutical companies and other biotech companies developing therapies for neurological disorders. Their advantage lies in their precision medicine approach, but they face challenges related to clinical trial execution and funding.
Growth Trajectory and Initiatives
Historical Growth: Limited historical growth data is available due to the company's recent founding.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst projections vary widely based on the potential of their drug candidates.
Recent Initiatives: Recent initiatives include advancing RAP-219 into Phase 1 clinical trials and expanding its pipeline of drug candidates.
Summary
Rapport Therapeutics is an early-stage biotech company with a promising pipeline of precision medicines for neurological disorders. Their focus on selective neuronal modulation and experienced management team are strengths. However, they face typical challenges associated with drug development, including clinical trial risk and competition from larger companies. They need to secure funding and execute clinical trials successfully to achieve their growth potential.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings (e.g., S-1)
- Industry reports
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made based on thorough research and consultation with a financial advisor. Market share estimates are approximate and may vary depending on the source.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Rapport Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2024-06-07 | CEO, President, Treasurer & Director Mr. Abraham N. Ceesay M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 69 | Website https://www.rapportrx.com |
Full time employees 69 | Website https://www.rapportrx.com | ||
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. The company was formerly known as Precision Neuroscience NewCo, Inc. and changed its name to Rapport Therapeutics, Inc. in October 2022. Rapport Therapeutics, Inc. was incorporated in 2022 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.